CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $54,260,677
- in 4 filings, $54.3M under 10b5-1 plans
Net −$54,220,677. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-20 | Kerr Douglas Head of R&D and CMO | Grant or award | +8,000 | 170,564 | ||
| 2026-10-20 | Kerr Douglas Head of R&D and CMO | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-10-02 | Posner Brian S Director | Purchase | +2,500 | $16.00 | $40K | 27,000 |
| 2026-09-08 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −185 | $18.88 | $3K | 152,897 |
| 2026-09-08 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −1,290 | $18.88 | $24K | 162,564 |
| 2026-09-08 | Cox John CEO & President | Sale 10b5-1 | −5,658 | $18.88 | $107K | 357,507 |
| 2026-09-04 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −900 | $24.35 | $22K | 153,082 |
| 2026-09-04 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −3,745 | $24.35 | $91K | 163,854 |
| 2026-08-14 | Rhodes Jason P Director | Sale 10b5-1 | −1,359,674 | $25.00 | $34.0M | 2,441,454 |
| 2026-08-14 | Rhodes Jason P Director | Sale 10b5-1 | −478,377 | $25.00 | $12.0M | 567,358 |
| 2026-08-14 | Rhodes Jason P Director | Sale 10b5-1 | −322,465 | $25.00 | $8.1M | 428,946 |
| 2026-08-13 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −226 | $26.28 | $6K | 153,982 |
| 2026-08-13 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −1,556 | $26.28 | $41K | 167,599 |
| 2026-08-13 | Lucera Erick Chief Financial Officer | Sale 10b5-1 | −1,797 | $26.28 | $47K | 119,766 |
| 2026-08-13 | Rhodes Jason P Director | Sale 10b5-1 | −268,354 | $26.20 | $7.0M | 3,801,128 |
| 2026-08-13 | Rhodes Jason P Director | Sale 10b5-1 | −94,415 | $26.20 | $2.5M | 1,045,735 |
| 2026-08-13 | Rhodes Jason P Director | Sale 10b5-1 | −63,643 | $26.20 | $1.7M | 751,411 |
| 2026-08-13 | Cox John CEO & President | Sale 10b5-1 | −4,986 | $26.28 | $131K | 363,165 |
| 2026-07-27 | Kersten Dirk Director | Sale 10b5-1 | −256,072 | $25.50 | $6.5M | 3,592,184 |
| 2026-07-27 | Kersten Dirk Director | Sale 10b5-1 | −5,388 | $26.04 | $140K | 3,586,796 |
Page 1 of 29 · 561 trades